{"id":"CHEMBL104815","canonicalSmiles":"CC(=O)N1CCN(C(=O)[C@H](Cc2cccc(C(=N)N)c2)NS(=O)(=O)c2ccc3ccccc3c2)CC1","inchiKey":"ZUWBXGHMVKDMQO-DEOSSOPVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL104815","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04125"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1094636","canonicalSmiles":"NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12","inchiKey":"PCHKPVIQAHNQLW-CQSZACIVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NIRAPARIB","yearOfFirstApproval":2017,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Zejula"],"synonyms":["JNJ-64091742","MK-4827","MK4827","Niraparib","ZL-2306"],"crossReferences":{"DailyMed":["niraparib%20tosylate"],"drugbank":["DB11793"]},"childChemblIds":["CHEMBL3989922"],"linkedTargets":{"rows":["ENSG00000143799","ENSG00000129484"],"count":2},"linkedDiseases":{"rows":["EFO_1000412","EFO_0003869","EFO_0000365","EFO_0001075","MONDO_0007254","EFO_1000657","EFO_0004230","EFO_0004252","MONDO_0002087","EFO_0000305","MONDO_0001187","MONDO_0000548","MONDO_0001056","EFO_1000044","MONDO_0002158","EFO_0000588","EFO_0000564","MONDO_0002974","MONDO_0008903","EFO_1000251","EFO_0000196","EFO_0008528","EFO_0000673","EFO_0000707","EFO_0002617","EFO_0000616","EFO_0002618","Orphanet_145","EFO_0006859","EFO_0003893","MONDO_0008170","EFO_1001512","MONDO_0008315","EFO_0003060","EFO_0001663","EFO_0000311","EFO_0003863","EFO_0000304","EFO_0001061","EFO_0000095","EFO_1001100","EFO_0000174","EFO_0002517","MONDO_0011962","EFO_0000702","EFO_0000574","MONDO_0024880","EFO_0000519","EFO_0000181"],"count":49},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 5 approved and 38 investigational indications."}
{"id":"CHEMBL1096380","canonicalSmiles":"CC(C)(C)c1[nH]cnc1/C=c1\\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O","inchiKey":"UNRCMCRRFYFGFX-TYPNBTCFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PLINABULIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NPI-2358","Plinabulin"],"crossReferences":{"drugbank":["DB05992"]},"childChemblIds":["CHEMBL4063810"],"linkedTargets":{"rows":["ENSG00000261456","ENSG00000167553","ENSG00000127824","ENSG00000188229","ENSG00000198033","ENSG00000258947","ENSG00000152086","ENSG00000196230","ENSG00000104833","ENSG00000167552","ENSG00000137267","ENSG00000101162","ENSG00000137285","ENSG00000123416","ENSG00000176014"],"count":15},"linkedDiseases":{"rows":["MONDO_0001475","EFO_0000702","EFO_0001378","EFO_0003060","EFO_0000311"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL1198857","canonicalSmiles":"OCc1cc([C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O","inchiKey":"DAFYYTQWSAWIGS-DEOSSOPVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VILANTEROL","yearOfFirstApproval":2013,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["GW-642444","GW-642444X","GW642444","GW642444X","Vilanterol"],"crossReferences":{"DailyMed":["vilanterol%20trifenatate"],"drugbank":["DB09082"],"chEBI":["75037"]},"childChemblIds":["CHEMBL1084172","CHEMBL1084647"],"linkedTargets":{"rows":["ENSG00000169252"],"count":1},"linkedDiseases":{"rows":["EFO_0000464","EFO_0006505","MONDO_0004979","EFO_0000341"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 4 approved and 2 investigational indications."}
{"id":"CHEMBL1200322","canonicalSmiles":"CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21.O=C(O)C(=O)O","inchiKey":"KTGRHKOEFSJQNS-BDQAORGHSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"ESCITALOPRAM OXALATE","yearOfFirstApproval":2002,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1508","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Escitalopram oxalate","Lexapro"],"synonyms":["Citalopram oxalate, (s)-","Escitalopram (as oxalate)","Escitalopram oxalate","LU 26-054-0","LU-26-054-0","LU-26-054-O","NSC-758934"],"crossReferences":{"DailyMed":["escitalopram%20oxalate"],"PubChem":["144205088","170465453","26749920","49681820"]},"linkedTargets":{"rows":["ENSG00000108576"],"count":1},"linkedDiseases":{"rows":["EFO_1001892","EFO_0004262","EFO_0006788","MONDO_0002050","MONDO_0002009","EFO_1001919","EFO_0003761"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 4 approved and 3 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1200409","canonicalSmiles":"CCN(CC)CC(=O)Nc1c(C)cccc1C.Cl.O","inchiKey":"YECIFGHRMFEPJK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"LIDOCAINE HYDROCHLORIDE","yearOfFirstApproval":1948,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL79","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Akten","Alphacaine hydrochloride","Anestacon","Anodesyn","Bismodyne","Bradosol plus","Calgel","Co-phenylcaine fte","Denela","Dequaspray","Emla","Germoloids","Germoloids complete","Glydo","Hemocane","Iglu","Instillagel","Laryng-o-jet kit","Laryngojet","Laryngotracheal anesthesia kit","Lido hcl","Lidocaine hydrochloride","Lidocaine hydrochloride preservative free","Lidocaine hydrochloride viscous","Lidocaine viscous","Lidocaton","Lidopen","Lignokent","Lignospan special","Lignostab","Lignostab a 100","Lignostab n","Lignostab-a","Lta ii kit","Medijel","Oragard","Pediatric lta kit","Preparation h","Rexocaine","Versatis","Xylocaine","Xylocaine dental","Xylocaine preservative free","Xylocaine viscous","Xylotox e80","Zingo"],"synonyms":["Lidocaine hcl","Lidocaine hydrochloride","Lidocaine hydrochloride monohydrate","Lidocaine hydrochloride usp","Lidocaini hydrochloridum","Lignocaine (as hydrochloride)","Lignocaine hydrochloride","NSC-757420","Xylocaine hydrochloride"],"crossReferences":{"DailyMed":["lidocaine%20hydrochloride"],"PubChem":["56422178"],"chEBI":["60791"]},"linkedTargets":{"rows":["ENSG00000153253","ENSG00000185313","ENSG00000183873","ENSG00000136546","ENSG00000144285","ENSG00000169432","ENSG00000168356","ENSG00000007314","ENSG00000136531","ENSG00000196876"],"count":10},"linkedDiseases":{"rows":["EFO_1001896","HP_0000989","EFO_0005952","EFO_0002950","EFO_0000565","MONDO_0005277","HP_0100543","EFO_1001996","EFO_1001898","EFO_0009552","EFO_0000400","EFO_0007490","EFO_1001250","EFO_0002618","HP_0000360","HP_0009762","HP_0003418","EFO_1001054","EFO_0003843","HP_0002315","EFO_1000941","EFO_0001663","EFO_0000537","EFO_0000311","MONDO_0002691","EFO_0000546","EFO_0003890","HP_0000951","EFO_0000649","EFO_0003957","EFO_0004888","EFO_0000574","MONDO_0002258"],"count":33},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and has 3 approved and 12 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1200598","canonicalSmiles":"CC/C(=C(/CC)c1ccc(OP(=O)(O)O)cc1)c1ccc(OP(=O)(O)O)cc1","inchiKey":"NLORYLAYLIXTID-ISLYRVAYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIETHYLSTILBESTROL DIPHOSPHATE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Fosfestrol","Stilphostrol"],"synonyms":["Diethylstilbestrol diphosphate","Fosfestrol"],"crossReferences":{"PubChem":["144206347","50125929"],"chEBI":["4532"]},"linkedTargets":{"rows":["ENSG00000091831","ENSG00000140009"],"count":2},"linkedDiseases":{"rows":["EFO_0000616"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for neoplasm."}
{"id":"CHEMBL1200665","canonicalSmiles":"CCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1.Cl","inchiKey":"SHTAFWKOISOCBI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIPHENOXYLATE HYDROCHLORIDE","yearOfFirstApproval":1960,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201294","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Diphenoxylate HCl","Diphenoxylate hcl","Diphenoxylate hydrochloride","Diphenoxylate hydrochloride cii","Diphenoxylati hydrochloridum","R-1132 (ANTIPERISTALTIC)"],"crossReferences":{"DailyMed":["diphenoxylate%20hydrochloride"],"PubChem":["144206146","144206378","170465332","49681550"],"chEBI":["59784"]},"linkedTargets":{"rows":["ENSG00000112038"],"count":1},"linkedDiseases":{"rows":["EFO_0000304"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960."}
{"id":"CHEMBL1200744","canonicalSmiles":"[18F-].[Na+]","inchiKey":"PUZPDOWCWNUUKD-ULWFUOSBSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"SODIUM FLUORIDE F 18","yearOfFirstApproval":1972,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1528","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Fluorine f-18","Sodium fluoride f 18","Sodium fluoride f-18"],"synonyms":["18f","Fluorine f 18 sodium fluoride","Fluorine, f-18","Fluorine, isotope of mass 18","Fluorine-18","Sodium Fluoride (18F)","Sodium Fluoride (F18)","Sodium fluoride (18f)","Sodium fluoride (na18f)","Sodium fluoride f 18","Sodium fluoride f-18","Sodium fluoride, f-18","Sodium fluoride-18f","Sodium radiofluoride"],"crossReferences":{"DrugCentral":["4488"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and has 3 approved and 2 investigational indications."}
{"id":"CHEMBL1200773","canonicalSmiles":"Cc1cccc(C)c1NC(=O)C(C)N.Cl","inchiKey":"AMZACPWEJDQXGW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"TOCAINIDE HYDROCHLORIDE","yearOfFirstApproval":1984,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1762","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Tonocard","Xylotocan"],"synonyms":["Tocainide hcl","Tocainide hydrochloride","Tocainide monohydrochloride"],"crossReferences":{"PubChem":["144204283","170465114"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1200962","canonicalSmiles":"CO/N=C(\\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(C[N+]3(C)CCCC3)CS[C@H]12)c1csc(N)n1.Cl.O.[Cl-]","inchiKey":"LRAJHPGSGBRUJN-OMIVUECESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CEFEPIME HYDROCHLORIDE","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL186","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cefepime hydrochloride","Maxipime"],"synonyms":["BMY-28142 2HCL.H20","BMY-28142 2HCL.H2O","BMY-28142 DIHYDROCHLORIDE MONOHYDRATE","Cefepime (as hydrochloride)","Cefepime dihydrochloride hydrate","Cefepime hcl","Cefepime hydrochloride","Cefepime hydrochloride (arginine formulation)","Cefepime hydrochloride monohydrate","NSC-760051"],"crossReferences":{"DailyMed":["cefepime%20hydrochloride"],"PubChem":["144204352"],"chEBI":["31368"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 5 approved and 4 investigational indications."}
{"id":"CHEMBL121516","canonicalSmiles":"S=C(SSC(=S)N1CCCCC1)N1CCCCC1","inchiKey":"KNBRWWCHBRQLNY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BIS(PIPERIDINYLTHIOCARBONYL)DISULFIDE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-527035"],"crossReferences":{"PubChem":["144206707","170465709","50126325"],"drugbank":["DB14174"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1234085","canonicalSmiles":"CNS(=O)(=O)c1ccc(N/C=C2\\C(=O)Nc3ccccc32)cc1","inchiKey":"IKASAFLVQIJQOK-UVTDQMKNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1234085","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08122"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1234624","canonicalSmiles":"O=S(=O)(O)c1ccc2ccccc2c1","inchiKey":"KVBGVZZKJNLNJU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1234624","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144211974"],"drugbank":["DB08254"],"chEBI":["44229"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1234640","canonicalSmiles":"O=P(O)(O)O[P@](=O)(O)OC[C@H]1O[C@@H](n2cnc3c(NCc4ccccc4)ncnc32)[C@H](O)[C@@H]1O","inchiKey":"MRHGMAGSDAQUFH-LSCFUAHRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1234640","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB01893"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1256722","canonicalSmiles":"C[C@H]1C=C(c2csc(SC3=C(C(=O)O)N4C(=O)[C@H]([C@@H](C)O)[C@H]4[C@H]3C)n2)CN1","inchiKey":"XFGOMLIRJYURLQ-GOKYHWASSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RAZUPENEM","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["PZ-601","Razupenem","SM-216601","SMP-601"],"crossReferences":{"drugbank":["DB12587"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1442422","canonicalSmiles":"CN(C)CCN1C(=O)c2ccccc2N(C)c2ccccc21","inchiKey":"QPGGEKPRGVJKQB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIBENZEPIN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Dibenzepin"],"crossReferences":{"PubChem":["26754618","29216076"],"drugbank":["DB13225"]},"childChemblIds":["CHEMBL2104287"],"linkedTargets":{"rows":["ENSG00000103546","ENSG00000196639"],"count":2},"linkedDiseases":{"rows":["EFO_0003761"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for unipolar depression."}
{"id":"CHEMBL1489","canonicalSmiles":"Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1","inchiKey":"NMUSYJAQQFHJEW-KVTDHHQDSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AZACITIDINE","yearOfFirstApproval":2004,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Azacitidine","Onureg","Vidaza"],"synonyms":["5-azacitidine","Azacitidine","Ladakamycin","NSC-102816","U-18,496","U-18496","Vidaza"],"crossReferences":{"DailyMed":["azacitidine"],"PubChem":["124890084","144204583","144213302","170465076","17390033","26752817","50105470","50105471","50122846","56320704","56323580","90341307"],"Wikipedia":["Azacitidine"],"drugbank":["DB00928"],"chEBI":["2038"]},"childChemblIds":["CHEMBL3250420","CHEMBL3250421"],"linkedTargets":{"rows":["ENSG00000130816","ENSG00000119772"],"count":2},"linkedDiseases":{"rows":["EFO_1001257","EFO_0000637","EFO_0000681","EFO_1000657","Orphanet_848","EFO_0005952","EFO_1001951","EFO_0000565","EFO_0004251","EFO_0000339","MONDO_0002280","EFO_0000389","EFO_1000028","EFO_0000198","EFO_0002618","MONDO_0013730","EFO_0000220","EFO_0001642","MONDO_0008170","Orphanet_3389","MONDO_0044881","HP_0001873","MONDO_0008315","EFO_0000574","EFO_0001378","Orphanet_231214","EFO_0000569","MONDO_0009348","MONDO_0044903","MONDO_0007254","EFO_0000255","MONDO_0021063","EFO_1001480","EFO_0004289","EFO_0000673","EFO_0000326","EFO_0002427","EFO_0000183","MONDO_0020743","EFO_0000707","EFO_0010580","EFO_0002617","MONDO_0003478","MONDO_0000430","EFO_0000616","EFO_1001779","EFO_0006859","MONDO_0019457","EFO_0000403","EFO_0000222","MONDO_0007576","MONDO_0019469","EFO_0003060","EFO_0000311","EFO_1001934","EFO_0000211","EFO_0006861","EFO_0000095","EFO_0002517","MONDO_0018906","MONDO_0020077","MONDO_0024880","EFO_0003833","EFO_0003811"],"count":64},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 7 approved and 45 investigational indications."}
{"id":"CHEMBL1533310","canonicalSmiles":"Cl.Cl.NCCc1c[nH]cn1","inchiKey":"PPZMYIBUHIPZOS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"HISTAMINE DIHYDROCHLORIDE","maximumClinicalTrialPhase":4,"parentId":"CHEMBL90","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ceplene"],"synonyms":["Histamine dihydrochloride","Histamine dihydrocloride","Histamine hydrochloride","Histaminum hydrochloricum","NSC-257873","Peremin"],"crossReferences":{"PubChem":["50106398"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 4 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1564","canonicalSmiles":"CN1CCC(OC(c2ccccc2)c2ccccc2)CC1.Cl","inchiKey":"LPRLDRXGWKXRMQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIPHENYLPYRALINE HYDROCHLORIDE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1492","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Hispril","Histryl","Histryl paed","Lergoban"],"synonyms":["Diphenylpyraline HCl","Diphenylpyraline hcl","Diphenylpyraline hydrochloride","Diphenylpyraline teoclate","NSC-61825"],"crossReferences":{"PubChem":["11532996","144203970","170464816","26748003","26748004"],"chEBI":["31508"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."}
{"id":"CHEMBL159","canonicalSmiles":"CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1","inchiKey":"JXLYSJRDGCGARV-CFWMRBGOSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"VINBLASTINE","yearOfFirstApproval":1965,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["NSC-47842","Velban","Vinblastine","[3H]-Vinblastine"],"crossReferences":{"DailyMed":["vinblastine%20sulfate"],"Wikipedia":["Vinblastine"],"drugbank":["DB00570"]},"childChemblIds":["CHEMBL378544"],"linkedTargets":{"rows":["ENSG00000261456","ENSG00000188229","ENSG00000104833","ENSG00000137267","ENSG00000258947","ENSG00000101162","ENSG00000137285","ENSG00000196230","ENSG00000176014"],"count":9},"linkedDiseases":{"rows":["MONDO_0009348","EFO_0004708","EFO_0004281","MONDO_0003751","MONDO_0004192","EFO_0000756","EFO_0000681","MONDO_0002041","EFO_0005952","MONDO_0020654","MONDO_0001187","EFO_0000565","EFO_1000318","EFO_0000588","MONDO_0002974","EFO_0000389","MONDO_0002898","MONDO_0008903","EFO_0008528","EFO_0000326","EFO_0000183","EFO_0002617","EFO_1000158","EFO_0000616","EFO_0000220","EFO_0001642","MONDO_0008170","EFO_0009907","EFO_0000403","EFO_0000222","Orphanet_636","MONDO_0004986","MONDO_0008315","EFO_0003060","EFO_0000211","EFO_0006818","MONDO_0018201","EFO_0000574","MONDO_0002367","EFO_0006544","EFO_0000691","MONDO_0021637"],"count":42},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and has 6 approved and 34 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1615234","canonicalSmiles":"CO[C@@H]1/C=C/[C@H](C)[C@@H](O)C[C@@H](OC)/C=C/[C@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@@H](C)CCC(=O)[C@H](C)[C@@H](C/C=C/N(C)C=O)OC)OC(=O)/C=C/C=C(/C)C[C@@H](OC)CC2=CC(=O)O[C@H]([C@H]2O)[C@H](C)[C@@H](OC)C1","inchiKey":"MINVLQAHLUCDIO-GLLDUQGXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SPHINXOLIDE B","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04783"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1628502","canonicalSmiles":"CC(OC(=O)NCC1(CC(=O)O)CCCCC1)OC(=O)C(C)C","inchiKey":"TZDUHAJSIBHXDL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GABAPENTIN ENACARBIL","yearOfFirstApproval":2011,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Horizant"],"synonyms":["ASP-8825","ASP8825","GSK1838262","Gabapentin enacarbil","Gabapentin encarbil","Gsk-1838262","XP 13512","XP-13512","XP13512"],"crossReferences":{"DailyMed":["gabapentin%20enacarbil"],"drugbank":["DB08872"],"chEBI":["68840"]},"linkedTargets":{"rows":["ENSG00000153956"],"count":1},"linkedDiseases":{"rows":["Orphanet_294049","EFO_1000783","MONDO_0005277","EFO_0003086","EFO_0000474","EFO_0009430","MONDO_0004975","MONDO_0007079","EFO_0004270"],"count":9},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 3 approved and 4 investigational indications."}
{"id":"CHEMBL1651990","canonicalSmiles":"Clc1ccc(C(Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1","inchiKey":"ZCJYUTQZBAIHBS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FENTICONAZOLE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Fenticonazole"],"crossReferences":{"PubChem":["170466486"],"drugbank":["DB13434"],"chEBI":["83602"]},"childChemblIds":["CHEMBL2107703"],"description":"Small molecule drug with a maximum clinical trial phase of IV."}
{"id":"CHEMBL1729803","canonicalSmiles":"CCN(CC)CCn1c(=O)c(Cc2ccc(OC)cc2)nc2ccccc21","inchiKey":"MSPRUJDUTKRMLM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CAROVERINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Caroverine","Spasmium"],"crossReferences":{"PubChem":["144207061","174006990","90341829"],"drugbank":["DB13835"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1737","canonicalSmiles":"CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O","inchiKey":"DEIYFTQMQPDXOT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SILDENAFIL CITRATE","yearOfFirstApproval":1998,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL192","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Revatio","Sildenafil citrate","Viagra"],"synonyms":["NSC-744009","NSC-758669","Sildenafil (as citrate)","Sildenafil citrate","UK-92,480-10","UK-92480-10"],"crossReferences":{"DailyMed":["sildenafil%20citrate"],"PubChem":["144205270","170465285"],"Wikipedia":["Sildenafil"],"chEBI":["58987"]},"linkedTargets":{"rows":["ENSG00000138735"],"count":1},"linkedDiseases":{"rows":["EFO_0001361","EFO_0001365","EFO_0004234","EFO_0000464","HP_0000802","EFO_0000495","EFO_1001145","EFO_0003913","EFO_0003144","EFO_1001134","EFO_0000712","EFO_1000824","EFO_0003047","EFO_1001893","Orphanet_654","EFO_0009441","EFO_0000616","MONDO_0005149","EFO_1001017","EFO_0000545","EFO_1001103","Orphanet_422","EFO_1001986","MONDO_0008315","EFO_0000537","EFO_1000954","EFO_0000195","EFO_0000404","MONDO_0100096","EFO_1001827","EFO_0011023","HP_0100607","EFO_0000341","EFO_0003830","MONDO_0043510","EFO_0003833","EFO_0000519","MONDO_0021640","EFO_0000668"],"count":39},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 5 approved and 27 investigational indications."}
{"id":"CHEMBL1743007","drugType":"Antibody","blackBoxWarning":false,"name":"DARATUMUMAB","yearOfFirstApproval":2015,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["3003-005","Daratumumab","Daratumumab-fihj","Darzalex","HUMAX-CD 38","HuMax-CD38"],"crossReferences":{"DailyMed":["daratumumab"],"DrugCentral":["5063"]},"linkedTargets":{"rows":["ENSG00000004468"],"count":1},"linkedDiseases":{"rows":["EFO_0003073","EFO_0000209","EFO_0005558","EFO_1001469","EFO_0005952","Orphanet_85443","EFO_1001951","EFO_0007160","EFO_0002690","EFO_0000330","EFO_0000673","EFO_0000183","EFO_0000198","EFO_0009441","EFO_0000616","EFO_0005761","MONDO_0019465","EFO_0000220","EFO_0000349","EFO_0000403","EFO_0000222","EFO_1001875","EFO_0004599","MONDO_0008315","EFO_0003060","EFO_0000311","EFO_0006738","EFO_0000203","EFO_0000304","EFO_0000095","EFO_0006475","MONDO_0004975","EFO_0000574","EFO_1001051","EFO_0001378","EFO_0006544","MONDO_0018906","EFO_0000519","EFO_1001115"],"count":39},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 31 investigational indications."}
{"id":"CHEMBL174539","canonicalSmiles":"CCCS(=O)(=O)N1N=Cc2sc(C)cc2B1O","inchiKey":"TVXLILKNSPCVRB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL174539","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08605"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1889091","canonicalSmiles":"CN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1.Cl","inchiKey":"MSIJLVMSKDXAQN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHLORCYCLIZINE HYDROCHLORIDE","maximumClinicalTrialPhase":1,"parentId":"CHEMBL22150","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Di-paralene"],"synonyms":["AH-289","Chlorcyclizine hcl","Chlorcyclizine hydrochloride","Chlorcyclizine monohydrochloride","Chlorcyclizinium chloride","Histantin","NSC-169496","Perazil"],"crossReferences":{"PubChem":["144204062","56463096"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL190333","canonicalSmiles":"OCCC#Cc1nc(-c2ccc(F)cc2)c(-c2ccncc2)n1CCCc1ccccc1","inchiKey":"QSUSKMBNZQHHPA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RWJ-67657","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["RWJ-67657","Rwj-67657"],"crossReferences":{"PubChem":["137275843"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL191060","canonicalSmiles":"CCc1ccc(O[C@@H](Cc2ccccc2)C(=O)O)cc1","inchiKey":"CJMVTSLLWMPEKQ-INIZCTEOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL191060","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07842"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL200255","canonicalSmiles":"NS(=O)(=O)c1ccc(CNC(=O)c2cn[nH]c2-c2cc(Cl)c(O)cc2O)cc1","inchiKey":"OOHYJGNSESWEFT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL200255","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04588"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2103784","canonicalSmiles":"CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)O)C(C)C)C(C)C)C(C)C","inchiKey":"ZOEFCCMDUURGSE-SQKVDDBVSA-N","drugType":"Protein","blackBoxWarning":false,"name":"COSYNTROPIN","yearOfFirstApproval":1970,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cortrosyn","Cosyntropin","Synacthen","Synacthen depot"],"synonyms":["Corticotropin tetracosapeptide","Cosyntropin","Cosyntropin acetate","Cosyntropin hexaacetate","Tetracosactide","Tetracosactide acetate","Tetracosactide hexaacetate","Tetracosactide hexacetate","Tetracosactrin","Vicotrope"],"crossReferences":{"DailyMed":["cosyntropin"],"drugbank":["DB01284"],"chEBI":["3901"]},"linkedTargets":{"rows":["ENSG00000185231"],"count":1},"linkedDiseases":{"rows":["EFO_0004254","MONDO_0100062","HP_0002315","EFO_0000537"],"count":4},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 3 investigational indications."}
{"id":"CHEMBL2103812","canonicalSmiles":"N[C@H](CCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O)C(=O)O","inchiKey":"CATMPQFFVNKDEY-YPMHNXCESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GOLOTIMOD","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Golotimod","SCV-07"],"crossReferences":{"drugbank":["DB05475"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2104391","canonicalSmiles":"CCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2)[C@@H](C)O)C(=O)O","inchiKey":"UGOZVNFCFYTPAZ-IOXYNQHNSA-N","drugType":"Protein","blackBoxWarning":false,"name":"INSULIN DETEMIR","yearOfFirstApproval":2005,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ins levemir","Levemir","Levemir flexpen","Levemir flextouch","Levemir innolet","Levemir penfill"],"synonyms":["Detemir","Insulin detemir","Insulin detemir recombinant","Insulin,detemir,human","NN-304"],"crossReferences":{"DailyMed":["insulin%20detemir%20recombinant"],"DrugCentral":["4985"]},"linkedTargets":{"rows":["ENSG00000171105"],"count":1},"linkedDiseases":{"rows":["EFO_0003914","HP_0003124","MONDO_0005147","HP_0003074","EFO_0001645","Orphanet_586","MONDO_0005148","EFO_0000400","EFO_0000537"],"count":9},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 3 approved and 5 investigational indications."}
{"id":"CHEMBL2104805","canonicalSmiles":"CC1CN2CC(=O)Nc3ccc(Cl)cc3C2(c2ccccc2)O1","inchiKey":"VCCZBYPHZRWKFY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OXAZOLAM","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Hializan","Oxazolam","Serenal","Tranquit"],"crossReferences":{"drugbank":["DB15491"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2108038","drugType":"Antibody","blackBoxWarning":false,"name":"MATUZUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["EMD-72000","Matuzumab"],"linkedTargets":{"rows":["ENSG00000146648"],"count":1},"linkedDiseases":{"rows":["MONDO_0008170","EFO_0003060"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2108426","drugType":"Enzyme","blackBoxWarning":false,"name":"MONTEPLASE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cleactor","Monteplase"],"linkedTargets":{"rows":["ENSG00000122194"],"count":1},"linkedDiseases":{"rows":["EFO_0003827"],"count":1},"description":"Enzyme drug with a maximum clinical trial phase of III."}
{"id":"CHEMBL2108574","drugType":"Unknown","blackBoxWarning":false,"name":"ANTITHROMBIN III HUMAN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Kybernin","Thrombate iii"],"synonyms":["Antithrombin","Antithrombin iii","Antithrombin iii (human)","Antithrombin iii human","Antithrombin iii, human","Antithrombin iii,human","At iii","At-iii","Atenativ","Atnativ","Heparin cofactor b","Kybernin p","ORG 10849"],"description":"Unknown drug with a maximum clinical trial phase of IV (across all indications) and is indicated for recurrent thrombophlebitis and has 2 investigational indications."}
{"id":"CHEMBL2108703","drugType":"Enzyme","blackBoxWarning":false,"name":"LIPROTAMASE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Theraclec","Trizytek"],"synonyms":["ALTU-135","Liprotamase"],"description":"Enzyme drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2108785","drugType":"Antibody","blackBoxWarning":false,"name":"ZOLIMOMAB ARITOX","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Orthozyme cd5 plus"],"synonyms":["H-65-RTA","H-65RTA","H65-RTA","Orthozyme cd 5 plus","Xoma zyme h 65","ZX-CD5","Zolimomab aritox"],"description":"Antibody drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL2109191","drugType":"Antibody","blackBoxWarning":false,"name":"GALIXIMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Galiximab","IDEC-114"],"linkedTargets":{"rows":["ENSG00000121594"],"count":1},"linkedDiseases":{"rows":["EFO_0000574","EFO_0005952"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2109302","drugType":"Antibody","blackBoxWarning":false,"name":"MU-11-1F4 124I","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MU-11-1F4","Mu-11-1f4 124i"],"description":"Antibody drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2109474","drugType":"Antibody","blackBoxWarning":false,"name":"TRX-1","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["TRX-1"],"description":"Antibody drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL2109619","drugType":"Antibody","blackBoxWarning":false,"name":"TCN-032","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["TCN-032","Tcn-032"],"description":"Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2111286","canonicalSmiles":"CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Bi+3]","inchiKey":"XAUTYMZTJWXZHZ-UHFFFAOYSA-K","drugType":"Small molecule","blackBoxWarning":false,"name":"RANITIDINE BISMUTH CITRATE","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1790041","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Pylorid","Tritec"],"synonyms":["GR 122311X","GR-122311X","Ranitidine bismuth citrate","Ranitidine bismutrex"],"linkedTargets":{"rows":["ENSG00000113749"],"count":1},"linkedDiseases":{"rows":["EFO_0003948","HP_0004398","EFO_1000961"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for gastroesophageal reflux disease and peptic ulcer and has 1 investigational indication."}
{"id":"CHEMBL2151591","canonicalSmiles":"Cc1c(O)cc2c(c1C)O[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC2","inchiKey":"QUEDXNHFTDJVIY-DQCZWYHMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GAMMA-TOCOPHEROL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(r,r,r)-.gamma.-tocopherol",".gamma.-tocopherol","7,8-dimethyltocol","Gamma tocopherol","Gamma-tocopherol","J213.540J","O-xylotocopherol","Rrr-.gamma.-tocopherol"],"crossReferences":{"PubChem":["144207108"],"drugbank":["DB15394"],"chEBI":["18185"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2165620","canonicalSmiles":"O=C(O)c1ccc(NC(=O)[C@H](CC2CCCC2)n2cnc(C(F)(F)F)c2)nc1","inchiKey":"GKMLFBRLRVQVJO-ZDUSSCGKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PF-04991532","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Pf-04991532"],"crossReferences":{"drugbank":["DB11765"]},"linkedTargets":{"rows":["ENSG00000106633"],"count":1},"linkedDiseases":{"rows":["MONDO_0005148"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2359966","canonicalSmiles":"C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12.C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12.O.O.O=S(=O)(O)O","inchiKey":"ZHNFLHYOFXQIOW-LPYZJUEESA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"QUININE SULFATE","yearOfFirstApproval":2005,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL170","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Qualaquin","Quinate","Quinine sulfate"],"synonyms":["Anhydrous quinine sulfate","Chininum sulphuricum","FEMA NO. 2977","NSC-5362","NSC-757298","Quinamm","Quinine hemisulfate anhydrous","Quinine sulfate","Quinine sulfate (2:1)","Quinine sulfate anhydrous","Quinine sulfate dihydrate","Quinine sulfate hydrate","Quinine sulphate","Quinine, sulfate (2:1) (salt)"],"crossReferences":{"DailyMed":["quinine%20sulfate"],"PubChem":["144206988"],"chEBI":["52251"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for muscle cramp and plasmodium falciparum malaria and has 1 investigational indication. This drug has a black box warning from the FDA."}
{"id":"CHEMBL2367706","canonicalSmiles":"O=S(=O)(OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O)O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O","inchiKey":"JTZPPHUZZDKEOC-RBQAPOGLSA-A","drugType":"Unknown","blackBoxWarning":false,"name":"SUCRALFATE","yearOfFirstApproval":1981,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Antepsin","Carafate","Sucralfate","Ulcerlmin"],"synonyms":["Sucralfate"],"crossReferences":{"DailyMed":["sucralfate"],"DrugCentral":["4106"]},"childChemblIds":["CHEMBL3989780"],"linkedTargets":{"rows":["ENSG00000256713"],"count":1},"linkedDiseases":{"rows":["EFO_0004232","HP_0004398","EFO_0008533","EFO_0003948","EFO_0000337","EFO_0004607","EFO_0005628"],"count":7},"description":"Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 1 investigational indication."}
{"id":"CHEMBL2403238","canonicalSmiles":"C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12","inchiKey":"WCWSTNLSLKSJPK-LKFCYVNXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CABOTEGRAVIR","yearOfFirstApproval":2021,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Cabotegravir","GSK-1265744A","GSK1265744","GSK1265744A","GSK744","Gsk-1265744","Gsk744","S-265744"],"crossReferences":{"drugbank":["DB11751"]},"childChemblIds":["CHEMBL3137330"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 1 investigational indication."}
{"id":"CHEMBL2431525","canonicalSmiles":"C[C@]12CC[C@H]3[C@@H](CCC4=C(O)C(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O","inchiKey":"BQOIJSIMMIDHMO-FBPKJDBXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL2431525","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB01485"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL253582","canonicalSmiles":"OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O","inchiKey":"CZMRCDWAGMRECN-UGDNZRGBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SUCROSE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["GNE-410","NSC-406942","S-67F","Sucrose"],"crossReferences":{"PubChem":["144205646","144208595","144210728","26757665"],"Wikipedia":["Sucrose"],"drugbank":["DB02772"],"chEBI":["17992"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL256725","canonicalSmiles":"COc1cc(Nc2nccc(Nc3c(Cl)ccc4c3OCO4)n2)cc(OC)c1OC","inchiKey":"HMKLUOPMOJOUDZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL256725","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07250"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL259084","canonicalSmiles":"O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1","inchiKey":"HHFBDROWDBDFBR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MLN-8054","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MLN 8054","MLN-8054","Mln-8054","Mln8054"],"crossReferences":{"PubChem":["103904597","174006403","50100109"],"drugbank":["DB13061"]},"childChemblIds":["CHEMBL3586469"],"linkedTargets":{"rows":["ENSG00000087586"],"count":1},"linkedDiseases":{"rows":["EFO_0003869","EFO_0003860","EFO_0004288","EFO_0000311"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL282052","canonicalSmiles":"Cc1ccccc1-n1c(C)nc2ccccc2c1=O","inchiKey":"JEYCTXHKTXCGPB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"METHAQUALONE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"],"classes":["Misuse"],"year":1984},"tradeNames":[],"synonyms":["CI-705","CN 38703","CN-38703","Methaqualone","Methaqualoneinone","Metolquizolone","NSC-111388","NSC-111388-","NSC-126877","NSC-631628","QZ-2","R-148","TR-495"],"crossReferences":{"PubChem":["144206055","144206422","24804237"],"Wikipedia":["Methaqualone"],"drugbank":["DB04833"],"chEBI":["6821"]},"childChemblIds":["CHEMBL2106829"],"description":"Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in United States  in 1984 due to Misuse."}
{"id":"CHEMBL291657","canonicalSmiles":"C#CCN(c1nc(-c2cc(C)c(OC)cc2Cl)c(C)s1)[C@@H](CC1CC1)c1ccc(C)c(F)c1","inchiKey":"IEAKXXNRGSLYTQ-DEOSSOPVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SSR125543","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Crinecerfont","Nbi-74788","Ssr 125543","Ssr-125543","Ssr125543"],"crossReferences":{"chEBI":["34969"]},"childChemblIds":["CHEMBL1628268"],"linkedTargets":{"rows":["ENSG00000120088"],"count":1},"linkedDiseases":{"rows":["MONDO_0002050","Orphanet_418"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL296522","canonicalSmiles":"COc1cc(N)c(Cl)cc1C(=O)NC1CCN2CCCC1C2","inchiKey":"GZSKEXSLDPEFPT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RENZAPRIDE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ATL-1251","Renzapride"],"linkedTargets":{"rows":["ENSG00000149305","ENSG00000164270","ENSG00000186090","ENSG00000178084","ENSG00000186038","ENSG00000166736"],"count":6},"linkedDiseases":{"rows":["EFO_0000555"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL30219","canonicalSmiles":"C=CCC1(C(C)C#CCC)C(=O)[N-]C(=O)N(C)C1=O.[Na+]","inchiKey":"KDXZREBVGAGZHS-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":true,"name":"METHOHEXITAL SODIUM","yearOfFirstApproval":1960,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL7413","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Brevimytal","Brevital","Brevital sodium","Brietal","Brietal sod","Methohexitone"],"synonyms":["Enallynymal sodium","Methohexital sodium","Methohexital sodium salt","Sodium methohexital"],"crossReferences":{"DailyMed":["methohexital%20sodium"],"chEBI":["6834"]},"linkedTargets":{"rows":["ENSG00000145864","ENSG00000166206","ENSG00000163288"],"count":3},"linkedDiseases":{"rows":["MONDO_0002050"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960. This drug has a black box warning from the FDA."}
{"id":"CHEMBL3039514","canonicalSmiles":"COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(-c2ccc3c(c2)O[C@@H](c2ccccc2)n2c-3cc3cc(-c4c[nH]c([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)n4)ccc32)c[nH]1)C(C)C","inchiKey":"BVAZQCUMNICBAQ-PZHYSIFUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ELBASVIR","yearOfFirstApproval":2016,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Elbasvir","MK-8742"],"crossReferences":{"DailyMed":["elbasvir"],"drugbank":["DB11574"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for viral disease and chronic hepatitis c virus infection and has 2 investigational indications."}
{"id":"CHEMBL3039520","canonicalSmiles":"CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1","inchiKey":"XEDHVZKDSYZQBF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LASMIDITAN","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["COL-144","LY573144","Lasmiditan"],"crossReferences":{"DailyMed":["lasmiditan%20succinate"],"drugbank":["DB11732"]},"childChemblIds":["CHEMBL3039526"],"linkedTargets":{"rows":["ENSG00000179097"],"count":1},"linkedDiseases":{"rows":["MONDO_0005277","EFO_0003890"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for migraine disorder and has 2 investigational indications."}
{"id":"CHEMBL3039540","drugType":"Antibody","blackBoxWarning":false,"name":"ADUCANUMAB","yearOfFirstApproval":2021,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Aduhelm"],"synonyms":["Aducanumab","Aducanumab-avwa","BIIB-037","BIIB037"],"linkedTargets":{"rows":["ENSG00000142192"],"count":1},"linkedDiseases":{"rows":["MONDO_0004975"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for alzheimer disease."}
{"id":"CHEMBL3039547","drugType":"Gene","blackBoxWarning":false,"name":"PEXASTIMOGENE DEVACIREPVEC","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["JX-594","Pexastimogene devacirepvec"],"description":"Gene drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."}
{"id":"CHEMBL306700","canonicalSmiles":"CCOc1ccccc1OCC1CNCCO1","inchiKey":"YWPHCCPCQOJSGZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"VILOXAZINE","yearOfFirstApproval":2021,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Viloxazin","Viloxazine"],"crossReferences":{"Wikipedia":["Viloxazine"],"drugbank":["DB09185"]},"childChemblIds":["CHEMBL2106483"],"linkedTargets":{"rows":["ENSG00000103546"],"count":1},"linkedDiseases":{"rows":["EFO_0003888","EFO_0003761"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for attention deficit hyperactivity disorder and unipolar depression. This drug has a black box warning from the FDA."}
{"id":"CHEMBL3137354","drugType":"Antibody","blackBoxWarning":false,"name":"LULIZUMAB PEGOL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMS-931699","Lulizumab pegol"],"linkedTargets":{"rows":["ENSG00000178562"],"count":1},"linkedDiseases":{"rows":["MONDO_0004670"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL3140361","canonicalSmiles":"CC[C@@H](CO)NCCN[C@@H](CC)CO.Cl.Cl","inchiKey":"AUAHHJJRFHRVPV-BZDVOYDHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ETHAMBUTOL HYDROCHLORIDE","yearOfFirstApproval":1967,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL44884","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ethambutol hydrochloride","Myambutol","Mynah 200","Mynah 250","Mynah 300","Mynah 365"],"synonyms":["CL 40881","CL-40881","Dadibutol","Dexambutol","Ebutol","Etapiam","Ethambutol dihydrochloride","Ethambutol hcl","Ethambutol hydrochloride","Ethambutoli hydrochloridum","Etibi","Mycobutol","NSC-757022","Servambutol","Tambutol","Tibutol"],"crossReferences":{"DailyMed":["ethambutol%20hydrochloride"],"PubChem":["144204045","170465115"],"chEBI":["4878"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for pulmonary tuberculosis and tuberculosis and has 2 investigational indications."}
{"id":"CHEMBL3182355","canonicalSmiles":"C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@H]2O","inchiKey":"MEHHPFQKXOUFFV-OWSLCNJRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL3182355","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144207737","144213956"],"drugbank":["DB11551"],"chEBI":["35018"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3185390","canonicalSmiles":"CC(=O)Nc1ccc(S(=O)(=O)Cl)cc1","inchiKey":"GRDXCFKBQWDAJH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL3185390","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144209754"],"drugbank":["DB12337"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL31871","canonicalSmiles":"Cc1c(Sc2ccccc2)n(COCCO)c(=O)[nH]c1=O","inchiKey":"HDMHBHNRWDNNCD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HEPT","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07892"],"chEBI":["43060"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3291398","canonicalSmiles":"C=C[C@]1(C)C[C@@H](OC(=O)CS[C@@H]2CC[C@@H](N)C[C@H]2O)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O","inchiKey":"KPVIXBKIJXZQJX-FCEONZPQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LEFAMULIN","yearOfFirstApproval":2019,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["BC-3781","Lefamulin"],"crossReferences":{"DailyMed":["lefamulin%20acetate"]},"childChemblIds":["CHEMBL3545309"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for bacterial pneumonia and bacterial disease and has 1 investigational indication."}
{"id":"CHEMBL3301606","canonicalSmiles":"CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1","inchiKey":"MPYACSQFXVMWNO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SOLCITINIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["G-154578","G154578","GLPG-0778","GLPG-0788","GLPG0778","GSK-2586184","GSK-2586184A","GSK2586184A","Glpg-0778","Gsk-2586184","Solcitinib"],"linkedTargets":{"rows":["ENSG00000162434"],"count":1},"linkedDiseases":{"rows":["EFO_0000729","EFO_0002690","EFO_0000676"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL332447","canonicalSmiles":"CC(C)NC(=O)C[C@H]1CCCN(C(=O)c2ccc(N3CCCC3)cc2Cl)c2ccccc21","inchiKey":"INGXCNVWWKKWOO-LJQANCHMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL332447","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB05838"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3545011","canonicalSmiles":"O[C@@H]1[C@@H](CSc2ccccc2F)O[C@@H](n2cnc3c(N[C@@H]4CCC[C@H]4O)ncnc32)[C@@H]1O","inchiKey":"IZRXENCTXNMAMI-DIJFLQFKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GS-9667","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CVT 3619","CVT-3619","Gs-9667"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3545155","canonicalSmiles":"COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1","inchiKey":"ZXBFYBLSJMEBEP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"JI-101","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Angiogenesis inhibitor ji-101","CGI-1842","JI-101","Ji-101"],"crossReferences":{"drugbank":["DB12744"]},"linkedTargets":{"rows":["ENSG00000128052","ENSG00000113721","ENSG00000196411"],"count":3},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0008170","MONDO_0021063"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL3545371","drugType":"Antibody","blackBoxWarning":false,"name":"DENINTUZUMAB MAFODOTIN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Denintuzumab mafodotin","SGN-19A","SGN-CD19A"],"linkedTargets":{"rows":["ENSG00000177455"],"count":1},"linkedDiseases":{"rows":["EFO_0000309","EFO_0000220","EFO_0000403","MONDO_0018906","EFO_1001469"],"count":5},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL3545387","drugType":"Small molecule","blackBoxWarning":false,"name":"SAD448","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Sad448"],"linkedTargets":{"rows":["ENSG00000188822","ENSG00000118432"],"count":2},"linkedDiseases":{"rows":["EFO_1001069"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL358850","canonicalSmiles":"C[C@@H](O)C(=O)O","inchiKey":"JVTAAEKCZFNVCJ-UWTATZPHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"D-LACTIC ACID","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["D-(-)-lactic acid","D-lactic acid","Lactate","Lactic acid, d-"],"crossReferences":{"PubChem":["144211160"],"drugbank":["DB03066"],"chEBI":["42111"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 19 investigational indications."}
{"id":"CHEMBL358860","canonicalSmiles":"O=P(O)(O)Oc1cccc2c1NCCC2","inchiKey":"NSJSAHCLJYVEDM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL358860","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03525"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL360055","canonicalSmiles":"CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC","inchiKey":"OZLPUNFFCJDMJD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GALLAMINE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Gallamine"],"crossReferences":{"PubChem":["11111237","11111238","124880248","26756602","90341095"]},"childChemblIds":["CHEMBL1200993"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."}
{"id":"CHEMBL36245","canonicalSmiles":"COc1cc(CN(C)c2cnc3nc(N)nc(N)c3c2)cc(OC)c1","inchiKey":"XWCCXDBXMCTZPW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL36245","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03987"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3707281","canonicalSmiles":"CC(O)C(=O)[O-].CC(O)C(=O)[O-].[Mg+2]","inchiKey":"OVGXLJDWSLQDRT-UHFFFAOYSA-L","drugType":"Small molecule","blackBoxWarning":false,"name":"MAGNESIUM LACTATE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Mag-tab sr"],"synonyms":["Anhydrous magnesium lactate, dl-","Dl-lactic acid magnesium salt","E-329","Ins no.329","Ins-329","Magnesium dl-lactate","Magnesium lactate","Magnesium lactate anhydrous","Magnesium lactate, anhydrous","Magnesium lactate, dl-","Magnesium, bis(lactato)-","Promagsan"],"crossReferences":{"DrugCentral":["4592"],"drugbank":["DB14515"]},"description":"Small molecule drug with a maximum clinical trial phase of IV."}
{"id":"CHEMBL383322","canonicalSmiles":"CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O","inchiKey":"BXNMTOQRYBFHNZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RESIQUIMOD","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CD-11301","CD11301","R-848","Resiquimod"],"crossReferences":{"Wikipedia":["Resiquimod"],"drugbank":["DB06530"],"chEBI":["36706"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 12 investigational indications."}
{"id":"CHEMBL3833331","drugType":"Small molecule","blackBoxWarning":false,"name":"BIIB061","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BIIB061","Biib061"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3924151","canonicalSmiles":"CNC(=N)NCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)NNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](Cc1ccc(O)cc1)NC(C)=O)[C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O","inchiKey":"MWXWMWSUUYXMRA-GRKBUMBKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TAK-448","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Tak-448"],"crossReferences":{"drugbank":["DB11975"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL396778","canonicalSmiles":"C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O","inchiKey":"NEMGRZFTLSKBAP-LBPRGKRZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SAFINAMIDE","yearOfFirstApproval":2017,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Xadago"],"synonyms":["EMD 1195686","EMD-1195686","Safinamide"],"crossReferences":{"DailyMed":["safinamide%20mesylate"],"Wikipedia":["Safinamide"],"drugbank":["DB06654"]},"childChemblIds":["CHEMBL48582"],"linkedTargets":{"rows":["ENSG00000069535"],"count":1},"linkedDiseases":{"rows":["EFO_1001050","EFO_0003086","MONDO_0005180","EFO_0001421"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for parkinson disease and has 3 investigational indications."}
{"id":"CHEMBL3989401","canonicalSmiles":"NCCC(O)(P(=O)([O-])O)P(=O)([O-])O.O.O.O.O.O.[Na+].[Na+]","inchiKey":"CZYWHNTUXNGDGR-UHFFFAOYSA-L","drugType":"Small molecule","blackBoxWarning":false,"name":"PAMIDRONATE DISODIUM","yearOfFirstApproval":1991,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL834","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Aredia","Pamidronate disodium"],"synonyms":["CGP 23339AE","CGP-23339AE","Disodium pamidronate","Pamidronate disodium","Pamidronate disodium hydrate"],"crossReferences":{"DailyMed":["pamidronate%20disodium"]},"linkedTargets":{"rows":["ENSG00000160752"],"count":1},"linkedDiseases":{"rows":["MONDO_0007254","EFO_0001378","Orphanet_666","EFO_1001164"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 4 investigational indications."}
{"id":"CHEMBL3989791","canonicalSmiles":"CC1CCCCC1(c1cccs1)N1CCCCC1","inchiKey":"DKFAAPPUYWQKKF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GACYCLIDINE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Gacyclidine","NST-001","Nst-001"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3989992","drugType":"Protein","blackBoxWarning":false,"name":"PEGILODECAKIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AM-0010","AM0010","Pegilodecakin"],"description":"Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3989999","drugType":"Antibody","blackBoxWarning":false,"name":"LETOLIZUMAB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMS-986004","Letolizumab"],"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL41169","canonicalSmiles":"CCC(=O)c1ccc2c(c1)N(CCCN(C)C)c1ccccc1S2","inchiKey":"ZQTVCQIJTREKSP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL41169","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["104171219","11111664","50111207","50111208","90340981"],"drugbank":["DB11540"]},"childChemblIds":["CHEMBL1256661"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4167360","canonicalSmiles":"Cc1cc([C@H](C)Nc2nccc(N3C(=O)OC[C@@H]3[C@@H](C)F)n2)ncc1-c1ccnc(C(F)(F)F)c1","inchiKey":"DCGDPJCUIKLTDU-QWQRMKEZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IDH305","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Idh305"],"linkedTargets":{"rows":["ENSG00000138413"],"count":1},"linkedDiseases":{"rows":["EFO_0000326","EFO_0000222","EFO_0000311"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL425616","canonicalSmiles":"CCn1c(Nc2ccccc2Cl)nc2cnc(Nc3c(F)cccc3F)nc21","inchiKey":"ZWKOUFZHPNIQSH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL425616","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08096"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4285417","canonicalSmiles":"C[C@@H]1COCCN1c1cc(C2([S@](C)(=N)=O)CC2)nc(-c2cc[nH]c3nccc2-3)n1","inchiKey":"OHUHVTCQTUDPIJ-JYCIKRDWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CERALASERTIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AZD6738","Atr kinase inhibitor azd6738","Azd 6738","Azd-6738","Ceralasertib"],"linkedTargets":{"rows":["ENSG00000175054"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0003869","EFO_0000637","EFO_0000756","MONDO_0008170","EFO_0000403","MONDO_0007254","EFO_0000313","EFO_0000228","EFO_0000305","EFO_0003060","MONDO_0008315","EFO_0000311","MONDO_0003059","MONDO_0001023","EFO_0000095","EFO_0000702","EFO_0000707","EFO_0000181"],"count":19},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 17 investigational indications."}
{"id":"CHEMBL4297212","canonicalSmiles":"Cl.NC(=O)OC[C@H](N)Cc1ccccc1","inchiKey":"KAOVAAHCFNYXNJ-SBSPUUFOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SOLRIAMFETOL HYDROCHLORIDE","yearOfFirstApproval":2019,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL4297620","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Sunosi"],"synonyms":["JZP-110 hydrochloride","Solriamfetol","Solriamfetol hydrochloride"],"crossReferences":{"DailyMed":["solriamfetol%20hydrochloride"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 4 approved indications."}
{"id":"CHEMBL4297281","canonicalSmiles":"CSCC[C@H](NC=O)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O","inchiKey":"WFZPJYYCTSHDJI-ATIWLJMLSA-N","drugType":"Protein","blackBoxWarning":false,"name":"FOXY-5","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Foxy-5","Foxy5","N-formyl-met-asp-gly-cys-glu-leu"],"crossReferences":{"drugbank":["DB13034"]},"description":"Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4297331","canonicalSmiles":"CN1C2C(=O)c3ccccc3C1C1=C2C(=O)c2ccccc2C1=O","inchiKey":"KAYRGFYBCCETPE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TU-100","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["TU100","Tu-100"],"crossReferences":{"drugbank":["DB12467"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4297551","drugType":"Protein","blackBoxWarning":false,"name":"EFGARTIGIMOD ALFA","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ARGX-113","Argx-113","Efgartigimod","Efgartigimod alfa"],"linkedTargets":{"rows":["ENSG00000104870"],"count":1},"linkedDiseases":{"rows":["EFO_0007160","EFO_0004991","EFO_0009538"],"count":3},"description":"Protein drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4297635","canonicalSmiles":"CCCCCc1cccc(CC(=O)O)c1","inchiKey":"PEGQOIGYZLJMIB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SETOGEPRAM","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Fezagepras","Pbi-4050","Setogepram"],"crossReferences":{"drugbank":["DB15447"]},"childChemblIds":["CHEMBL4799780"],"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL4297841","drugType":"Antibody","blackBoxWarning":true,"name":"TISOTUMAB VEDOTIN","yearOfFirstApproval":2021,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Tivdak"],"synonyms":["GCT1015-04","HuMax-TF-ADC","IGG1-1015-011-1006","TF-011-MMAE","Tisotumab vedotin","Tisotumab vedotin-tftv"],"linkedTargets":{"rows":["ENSG00000261456","ENSG00000117525","ENSG00000188229","ENSG00000104833","ENSG00000137267","ENSG00000258947","ENSG00000101162","ENSG00000196230","ENSG00000137285","ENSG00000176014"],"count":10},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0002158","MONDO_0002974","MONDO_0008170","MONDO_0002087"],"count":5},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for cervical cancer and has 4 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL4297914","drugType":"Protein","blackBoxWarning":false,"name":"TALDEFGROBEP ALFA","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMS-986089","Bms-986089","RO-7239361","RO7239361","Ro7239361","Taldefgrobep alfa","Talditercept alfa"],"description":"Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4298016","drugType":"Antibody","blackBoxWarning":false,"name":"FROVOCIMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Frovocimab","LY-3015014","LY3015014","Ly3015014"],"linkedTargets":{"rows":["ENSG00000169174"],"count":1},"linkedDiseases":{"rows":["HP_0003124","MONDO_0021187"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4298139","canonicalSmiles":"COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1C(=O)OC[n+]1cccc(C(=O)N[C@@H](CO)C(=O)O)c1.[Cl-]","inchiKey":"GONQEUJYYMYNMN-HWAJWLCKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SERDEXMETHYLPHENIDATE CHLORIDE","yearOfFirstApproval":2021,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL4301162","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["KP415 Cl","Serdexmethylphenidate chloride"],"linkedTargets":{"rows":["ENSG00000103546","ENSG00000142319"],"count":2},"linkedDiseases":{"rows":["EFO_0003888"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for attention deficit hyperactivity disorder."}
{"id":"CHEMBL435982","canonicalSmiles":"N[C@H](C[C@H](Cc1ccc2ccccc2c1)C(=O)O)C(=O)O","inchiKey":"YDWIUFASTTZKNI-UONOGXRCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL435982","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08272"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL453514","canonicalSmiles":"CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]1O","inchiKey":"ACTOXUHEUCPTEW-CEUOBAOPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SPIRAMYCIN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Rovamycin","Rovamycine 250"],"synonyms":["Acetylspiramycin","IL 5902","IL-5902","NSC-55926","NSC-64393","NSC-758472","RP 5337","RP-5337","Rovamicina","Rovamycine","Selectomycin","Spiramycin","Spiramycin I"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for bacterial disease and has 1 investigational indication."}
{"id":"CHEMBL454138","canonicalSmiles":"CC(C)OC(=O)C1=CN(C(=O)c2ccc(F)c(F)c2)CC(C)(C)c2c1[nH]c1ccccc21","inchiKey":"INASOKQDNHHMRE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TUROFEXORATE ISOPROPYL","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["FXR-450","Turofexorate isopropyl","WAY-362450","XL-335","XL335"],"crossReferences":{"PubChem":["137275949"],"drugbank":["DB12719"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL456145","canonicalSmiles":"C1Cc2[nH]nc(-c3nn[nH]n3)c2C1","inchiKey":"LTQYSJKGRPGMPO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MK-0354","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MK-0354"],"crossReferences":{"PubChem":["137275966"],"drugbank":["DB05939"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4594587","drugType":"Oligonucleotide","blackBoxWarning":false,"name":"ELUFORSEN","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Eluforsen","QR-010","Qr-010"],"description":"Oligonucleotide drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL46085","canonicalSmiles":"N[C@H]1CCc2ccccc2[C@H]1O","inchiKey":"IIMSEFZOOYSTDO-VHSXEESVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL46085","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07597"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4650447","drugType":"Unknown","blackBoxWarning":false,"name":"RO-0622","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Azvudine","RO 0622","Ro-0622"],"description":"Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL4650450","drugType":"Unknown","blackBoxWarning":false,"name":"BIIB-068","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BIIB-068","BIIB068","Biib-068","Biib068"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL472879","canonicalSmiles":"Cc1nc(-c2ccccn2)nc(NCCc2ccccc2)c1Cl","inchiKey":"HIUOABSWQSUEGK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GNF-Pf-359","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GNF-Pf-359"],"crossReferences":{"drugbank":["DB07901"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL479843","canonicalSmiles":"CC(O)C[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O","inchiKey":"KOGFZZYPPGQZFZ-QVAPDBTGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL479843","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB13121"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4802184","drugType":"Unknown","blackBoxWarning":false,"name":"TRIMIX","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Trimix"],"description":"Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL500883","canonicalSmiles":"Cn1ccc(N)nc1=O","inchiKey":"HWPZZUQOWRWFDB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"1-Methylcytosine","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["1-Methylcytosine"],"crossReferences":{"drugbank":["DB04314"],"chEBI":["39624"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL507419","canonicalSmiles":"Cc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1N","inchiKey":"XXYTXQGCRQLRHA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"METAHEXAMIDE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Glyhexylamide","Metahexamide","Metahexanamide"],"crossReferences":{"Wikipedia":["Metahexamide"],"drugbank":["DB13675"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL55068","canonicalSmiles":"O=C(O)CCCCCCCCCCCO","inchiKey":"ZDHCZVWCTKTBRY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"12-Hydroxy-Dodecanoic Acid","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["12-Hydroxy-Dodecanoic Acid"],"crossReferences":{"drugbank":["DB03704"],"chEBI":["39567"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL553204","canonicalSmiles":"COc1ccc(-c2oc3c(CC=C(C)C)c(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)cc(O)c3c(=O)c2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)cc1","inchiKey":"TZJALUIVHRYQQB-XLRXWWTNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ICARIIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Epimedii herba icariin","Icariin"],"crossReferences":{"PubChem":["26719816"],"Wikipedia":["Icariin"],"drugbank":["DB12052"],"chEBI":["78420"]},"description":"Small molecule drug with a maximum clinical trial phase of III."}
{"id":"CHEMBL561057","canonicalSmiles":"CC(C)=CCC/C(C)=C/CNCCNC1C2CC3CC(C2)CC1C3","inchiKey":"JFIBVDBTCDTBRH-REZTVBANSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SQ109","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-722041","SQ-109","SQ109","Sq-109","Sq109"],"crossReferences":{"drugbank":["DB05186"]},"childChemblIds":["CHEMBL3140371","CHEMBL570170"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL572546","canonicalSmiles":"Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OS(=O)(=O)O)[C@@H](O)[C@H]1O","inchiKey":"IRLPACMLTUPBCL-KQYNXXCUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"Adenosine-5'-Phosphosulfate","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Adenosine-5'-Phosphosulfate"],"crossReferences":{"drugbank":["DB03708"],"chEBI":["17709"]},"childChemblIds":["CHEMBL578658"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL572881","canonicalSmiles":"CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21","inchiKey":"RAHBGWKEPAQNFF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MOTESANIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AMG 706","AMG-706","Motesanib"],"crossReferences":{"PubChem":["137276049","50100087"],"drugbank":["DB05575"],"chEBI":["51098"]},"childChemblIds":["CHEMBL2107357"],"linkedTargets":{"rows":["ENSG00000134853","ENSG00000128052","ENSG00000165731","ENSG00000102755","ENSG00000037280","ENSG00000113721","ENSG00000157404"],"count":7},"linkedDiseases":{"rows":["EFO_0002618","EFO_0000616","MONDO_0021058","EFO_0007331","MONDO_0002108","MONDO_0008170","Orphanet_44890","MONDO_0007254","EFO_1000657","MONDO_0007576","MONDO_0021063","EFO_0004243","MONDO_0002087","EFO_0003060","EFO_1000218","MONDO_0002158","Orphanet_238510","MONDO_0008903","EFO_0000574"],"count":19},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 18 investigational indications."}
{"id":"CHEMBL6885","canonicalSmiles":"Nc1ccc2nc(N)nc(N)c2c1","inchiKey":"LJBWEZVYRBKOCI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"QUINAZOLINE-2,4,6-TRIAMINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Quinazoline-2,4,6-Triamine"],"crossReferences":{"drugbank":["DB02532"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL853","canonicalSmiles":"Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1","inchiKey":"WREGKURFCTUGRC-POYBYMJQSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"ZALCITABINE","yearOfFirstApproval":1992,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Hivid"],"synonyms":["Ddc (ddc)","Dideoxycytidine","Hivid","NSC-606170","RO 24-2027/000","RO-24-2027000","RO-242027000","Zalcitabine"],"crossReferences":{"PubChem":["11532889","144207040","144208853","144213486","170465128","17389522","26719633","26752752","49681781","50105404","50105405","90340765"],"Wikipedia":["Zalcitabine"],"drugbank":["DB00943"],"chEBI":["10101"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for viral disease and has 1 investigational indication. This drug has a black box warning from the FDA."}
